SOURCE: Horizon Pharma plc

Horizon Pharma plc

August 07, 2015 16:05 ET

Horizon Pharma plc Names George Hampton Executive Vice President, Global Orphan Business Unit and International Operations

DUBLIN, IRELAND--(Marketwired - Aug 7, 2015) -  Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon's Executive Committee.

"As we begin to enter the European and other international markets anchored by the potential near-term approval of RAVICTI, we need to leverage our U.S. orphan business unit to maximize the broader global orphan opportunity," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "George's experience and leadership will be integral in expanding the global penetration of RAVICTI and the potential U.S. opportunity for ACTIMMUNE in Friedreich's ataxia, if approved for that indication."

Hampton joined Horizon Pharma in 2008 as a consultant and full time as a group vice president, international operations in April 2015. Most recently, Hampton served as president and chief executive officer of a privately held technology company. He also has more than 20 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in the autoimmune (HUMIRA), primary care (CELEBREX), orthopedic, diabetes (BYETTA), anti-infectives and cardiovascular areas. This includes 10 product launches in roles of increasing responsibility in sales, international marketing and operations at G.D. Searle, Abbott (now AbbVie) and Amylin Pharmaceuticals. Hampton holds a bachelor's degree from Miami University in Oxford, Ohio.

"I'm excited to be a part the next phase of Horizon's growth and look forward to helping to drive the global opportunity for RAVICTI, maximize the potential U.S. expansion of ACTIMMUNE in Friedreich's ataxia, if approved, and driving international expansion through aggressive business development," said Hampton.

About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Pharma's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward Looking Statements
This press release contains forward-looking statements, including statements regarding Horizon Pharma's global expansion, the near-term approval of RAVICTI, the commercialization of RAVICTI in Europe and the potential approval of ACTIMMUNE in Friedreich's ataxia. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, global market conditions, whether Horizon Pharma will be able to enter into and expand to European and other international markets, whether the regulatory and other processes required for the approval and commercialization of RAVICTI or for ACTIMMUNE in Friedreich's ataxia will be completed in a timely manner or at all and the risks associated with the approval and commercialization of pharmaceutical products. For a further description of these and other risks facing Horizon, please see the risk factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon undertakes no obligation to update or revise these statements, except as may be required by law.

Contact Information

  • Contacts:

    Investors:
    John Thomas
    Executive Vice President, Strategy and Investor Relations
    Email Contact

    Tina Ventura
    Vice President, Investor Relations
    Email Contact

    Media:
    Geoff Curtis
    Group Vice President, Corporate Communications
    Email Contact

    Ireland Media:
    Ray Gordon
    Gordon MRM
    Email Contact